Boule Diagnostics Renews and Expands a Global Supply Agreement
Clinical Diagnostics Solutions (CDS), a Boule Diagnostics company in the US, announces that its supply agreement with a leading global In Vitro Diagnostics (IVD) customer has been renewed and expanded. The extended agreement is a result of the trust in CDS and the work to innovate for diagnostic technologies worldwide.
The agreement is expected to increase sales by approximately SEK 5 million once the project is fully implemented in 2027 and have a good operating margin. This expansion strengthens Boule’s strategic focus on long-term partnerships and profitable growth. “This agreement underlines the confidence in CDS’s solutions and strengthens our role in advancing health diagnostics globally,” says Torben Nielsen, CEO of Boule Diagnostics. “We look forward to continuing to deliver value and be a trusted supplier to our partners.”
Latest news
-
Kallelse till extra bolagsstämma i Boule Diagnostics AB (publ) 4 Nov, 2026
-
Boule Diagnostics AB resolves on a fully secured rights issue of approximately MSEK 93 with an over-allotment option of up to approximately MSEK 63 subject to approval by the Extraordinary General Meeting 4 Nov, 2026
-
Boule Diagnostics AB beslutar om en fullt säkerställd företrädesemission om cirka 93 MSEK med en övertilldelningsoption om upp till cirka 63 MSEK villkorat av godkännande från extra bolagsstämma 4 Nov, 2026
-
Boule Diagnostics renodlar verksamheten mot förbrukningsvaror, service och OEM – avvecklar instrumentverksamheten 4 Nov, 2026
-
Boule Diagnostics refocuses its operations on consumables, service and OEM – discontinues its instrument business 4 Nov, 2026
-
Boule Diagnostics delårsrapport Q3 2026 23 Oct, 2026
-
Boule Diagnostics Interim Report Q3 2026 23 Oct, 2026
-
Boule Diagnostics Strengthens Long-Term Strategic Collaboration in India 6 Oct, 2026